ArticleOpen forum infectious diseases2021
Integrase Strand Transfer Inhibitors and Weight Gain in Children and Youth With Perinatal Human Immunodeficiency Virus in the DC Cohort.
Article in Open forum infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Growth Outcomes After 48 Weeks of Dolutegravir in Children and Adolescents With HIV-1 in IMPAACT P1093 and IMPAACT 2019.Journal of the Pediatric Infectious Diseases Society · 2026Trial
- Changes in Body Mass Index in Children and Adolescents Living With Human Immunodeficiency Virus in Europe and Thailand Starting Dolutegravir.Open forum infectious diseases · 2025Article
- Cardiometabolic Health Burden in Pediatric HIV: Unmet Need in the Contemporary Antiretroviral Therapy Era.Cureus · 2025Review
- Assessing weight change in adolescents and young adults with perinatally acquired HIV and integrase inhibitor use.HIV medicine · 2025Article
- Weight Gain in HIV Adults Receiving Antiretroviral Treatment: Current Knowledge and Future Perspectives.Life (Basel, Switzerland) · 2024Review
- Prevalence of overweight and obesity among adolescents living with HIV after dolutegravir - based antiretroviral therapy start in Kampala, Uganda.AIDS research and therapy · 2024Article
- Adults with Perinatally Acquired HIV; Emerging Clinical Outcomes and Data Gaps.Tropical medicine and infectious disease · 2024Review
- Impact of the COVID-19 pandemic on BMI in youth living with HIV.SAGE open medicine · 2024Article
- Growth, weight gain and BMI in virally suppressed children on antiretroviral therapy with specific reference to dolutegravir.BMC pediatrics · 2023Article
- Evidence gaps on weight gain in people living with HIV: a scoping review to define a research agenda.BMC infectious diseases · 2023Article
- Preventing and diagnosing HIV-related comorbidities in adolescents.Topics in antiviral medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
We conducted a retrospective analysis of 38 children and youth with human immunodeficiency virus (aged 0-19 years) in the United States and report an increased rate of change of BMI-for-age
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.